← back to search

Hany A. Omar

University of Sharjah · AE
Area of research
Materials Chemistry · Organic Chemistry
Research interest
Research interests include Synthesis and biological activity, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, and Cancer, Hypoxia, and Metabolism.
h-index
44
citations
18,968
works
188
NIH funding
primary concept
email

Recent publications

Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies.
2026cited by 0position: contributordoi
Design, Synthesis, and Anticancer Evaluation of Novel MGBs with Alkyne-Linked Thiazole Moieties.
2025cited by 2position: contributordoi
Identifying the Impact of RelA Overexpression in Triple-Negative Breast Cancer Cells Using Mass Spectroscopy-based Proteomics and Metabolomics Analysis.
2025cited by 0position: contributordoi
Structure-Driven Mechanisms and Synergistic Approaches of Polyphyllin VII in Breast Cancer Therapy.
2025cited by 0position: contributordoi
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
2024cited by 3,311position: contributordoi
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
2024cited by 1,874position: contributordoi
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
2024cited by 1,817position: contributordoi
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
2024cited by 716position: contributordoi
Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021.
2024cited by 676position: contributordoi
Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
2024cited by 301position: contributordoi
The interplay of p38 MAPK signaling and mitochondrial metabolism, a dynamic target in cancer and pathological contexts.
2024cited by 35position: contributordoi
Unveiling the therapeutic potential of Taxifolin in Cancer: From molecular mechanisms to immune modulation and synergistic combinations.
2024cited by 6position: contributordoi
Autophagy inhibition potentiates energy restriction-induced cell death in hepatocellular carcinoma cells.
2024cited by 3position: contributordoi
Gelatin nanofibers: Recent insights in synthesis, bio-medical applications and limitations
Heliyon 2023cited by 125position: middledoi
Gelatin nanofibers: Recent insights in synthesis, bio-medical applications and limitations.
2023cited by 50position: contributordoi
New 1,2,3-triazole/1,2,4-triazole hybrids linked to oxime moiety as nitric oxide donor selective COX-2, aromatase, B-RAF<sup>V600E</sup> and EGFR inhibitors celecoxib analogs: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis and molecular modeling study.
2023cited by 19position: contributordoi
Targeting aldehyde dehydrogenase enzymes in combination with chemotherapy and immunotherapy: An approach to tackle resistance in cancer cells.
2023cited by 19position: contributordoi
Intranasal Nanotransferosomal Gel for Quercetin Brain Targeting: II. Antidepressant Effect in an Experimental Animal Model.
2023cited by 18position: contributordoi
Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19.
2023cited by 12position: contributordoi
Promising drug candidates for the treatment of polycystic ovary syndrome (PCOS) as alternatives to the classical medication metformin.
2023cited by 9position: contributordoi
Phthalazone tethered 1,2,3-triazole conjugates: In silico molecular docking studies, synthesis, in vitro antiproliferative, and kinase inhibitory activities.
2023cited by 8position: contributordoi
Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites.
2022cited by 20position: contributordoi
Impact of the ACE2 activator xanthenone on tacrolimus nephrotoxicity: Modulation of uric acid/ERK/p38 MAPK and Nrf2/SOD3/GCLC signaling pathways.
2022cited by 18position: contributordoi
Antibacterial Activity of Small Molecules Which Eradicate Methicillin-Resistant <i>Staphylococcus aureus</i> Persisters.
2022cited by 16position: contributordoi
The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene- Induced Hepatocarcinogenesis in Wistar Rats: The Impact of NF-κB/COX-2/PGE2 Signaling.
2022cited by 15position: contributordoi
Optimum inhibition of MCF-7 breast cancer cells by efficient targeting of the macropinocytosis using optimized paclitaxel-loaded nanoparticles.
2022cited by 13position: contributordoi
Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.
2022cited by 13position: contributordoi
Renoprotective effect of vinpocetine against ischemia/reperfusion injury: Modulation of NADPH oxidase/Nrf2, IKKβ/NF-κB p65, and cleaved caspase-3 expressions.
2022cited by 9position: contributordoi
Design, synthesis, and biological evaluation of novel pyrido-dipyrimidines as dual topoisomerase II/FLT3 inhibitors in leukemia cells.
2022cited by 9position: contributordoi
The inhibition of autophagy by spautin boosts the anticancer activity of fingolimod in multidrug-resistant hepatocellular carcinoma.
2022cited by 8position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 31 papers (2019–2026) · 5 papers (2020–2025)Sameh S. M. Soliman · The University of Texas Health Science Center5 papers (2020–2025)Taleb H. Al-Tel · American Chemical Society4 papers (2019–2021)Dana M. Zaher · University of Sharjah3 papers (2019–2021)Hesham R. El‐Seedi · Menoufia University3 papers (2021–2023)Hasan Y. Alniss · University of Toronto2 papers (2020–2025) · 2 papers (2022–2023)Mohammed Elmowafy · Al-Azhar University2 papers (2022–2023)Mai F. Tolba · Chapman University2 papers (2019–2019)Nermeen Yosri · National University of Malaysia2 papers (2021–2023)El-Shaimaa A. Arafa · Beni-Suef University2 papers (2019–2020)Maha Saber-Ayad · Cairo University2 papers (2020–2021)Narjes Saheb Sharif-Askari · University of Warwick2 papers (2020–2021)Hanan S. Anbar · Dubai Pharmacy College2 papers (2022–2023)Mohammed H. Elkomy · Cairo University2 papers (2022–2023)Alaa O. Hamouda · 2 papers (2024–2025)Sara I. Ibrahim · 2 papers (2024–2025)Mohamed‐Elamir F. Hegazy · Cairo University2 papers (2021–2021)Jianbo Xiao · Guangxi Medical University2 papers (2021–2021)